Method for constructing oocyte freezing injury model
By reducing the expression of LonP1 in oocytes, an oocyte freezing injury model was constructed, which solved the problem of lack of an ideal model in the existing technology, and successfully revealed the protein homeostasis imbalance and apoptosis mechanism of frozen oocytes. Studying the mechanism of oocyte cryoin injury and stress response provides an important theoretical basis.
Patent Information
- Application Number
- CN202411191579.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-28
- Publication Date
- 2024-11-12
AI Technical Summary
The lack of an ideal cellular model that simulates oocyte freezing damage has hindered the progress of in-depth study of oocyte freezing damage and stress response mechanisms, especially the specific role of LonP1 in frozen oocytes is not clear.
By reducing the expression of LonP1 in oocytes, using LonP1 inhibitor or siRNA to construct an oocyte freezing injury model, simulate the effect of freezing on oocytes, and study its protein homeostasis imbalance and apoptosis mechanism.
The oocyte freezing injury model was successfully constructed, revealing the close correlation between the decrease in LonP1 expression and the homeostasis imbalance of the protein of frozen oocytes and the apoptosis level, laying the foundation for in-depth study of the oocyte freezing injury and stress response mechanisms. .
Smart Images

Figure CN118931971A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the field of biotechnology, and in particular to a method for constructing an oocyte cryoinjury model. Background Art
[0002] Oocyte cryopreservation is a technology that achieves long-term storage of oocytes at ultra-low temperatures by inhibiting cell metabolism. Oocyte cryopreservation aims to preserve fertility by freezing gametes, and has been widely used in the preservation of rare species resources, the exchange of high-quality genetic resources, and human assisted reproductive technology. In addition, oocyte cryopreservation can be combined with a variety of embryo biotechnologies, such as in vitro fertilization, intracytoplasmic sperm injection, and embryo transfer, to provide guarantees for the in vitro production of embryos. Although oocyte cryopreservation has been widely used, the damage to oocytes caused by freezing is still unavoidable. Stable biological models are a useful tool for studying freezing damage, but there is currently no ideal method for constructing a cell model that simulates oocyte freezing damage, which to some extent hinders the progress of in-depth research on oocyte freezing damage and stress response mechanisms.
[0003] Protein homeostasis plays an important role in coping with external stress. The Lon protease family is a family of serine proteases that depends on ATP and plays a key role in maintaining protein homeostasis by degrading damaged or misfolded proteins. Among them, LonP1, as an important member of the Lon protease family, has a particularly significant function in this process. At present, the specific role of LonP1 in frozen oocytes has not been clearly revealed. Summary of the invention
[0004] The purpose of the present invention is to provide a method for constructing an oocyte cryoinjury model to solve the problems existing in the above-mentioned prior art. The present invention confirms that an oocyte cryoinjury model can be constructed by reducing the expression of LonP1 in oocytes, laying a model foundation for in-depth revelation of the mechanism of oocyte cryoinjury and stress response, and has important theoretical value and broad application prospects.
[0005] To achieve the above object, the present invention provides the following solutions:
[0006] The present invention provides application of a reagent for reducing the expression amount of LonP1 gene in oocytes in constructing an oocyte cryoinjury model.
[0007] Furthermore, the oocyte is a GV stage oocyte.
[0008] The present invention also provides a method for constructing an oocyte cryoinjury model, comprising the step of treating the oocyte with a reagent for reducing the expression level of the LonP1 gene.
[0009] Furthermore, the reagent for reducing the expression level of the LonP1 gene includes a LonP1 inhibitor and a siRNA for silencing the LonP1 gene.
[0010] Furthermore, the siRNA includes a sense strand as shown in SEQ ID NO.3 and an antisense strand as shown in SEQ ID NO.4.
[0011] Furthermore, the LonP1 inhibitor includes CDDO-me.
[0012] Furthermore, the oocyte is a GV stage oocyte.
[0013] The present invention also provides an oocyte cryoinjury model constructed by the method.
[0014] The present invention discloses the following technical effects:
[0015] The present invention studies fresh and frozen oocytes and finds that the decrease in LonP1 expression is closely related to the imbalance of protein homeostasis and the increase of apoptosis level in frozen oocytes. Further, by microinjecting siRNA that inhibits LonP1 gene expression, or treating oocytes with LonP1 inhibitor CDDO-me, LonP1 low-expressing oocytes are constructed, and it is found that LonP1 low-expressing oocytes have an imbalance of protein homeostasis and an increase in apoptosis level, which is similar to the relevant indicators of frozen oocytes. The present invention confirms that an oocyte cryoinjury model can be constructed by reducing the expression of LonP1 in oocytes, which lays a model foundation for in-depth revelation of the mechanism of oocyte cryoinjury and stress response, and has important theoretical value and broad application prospects. BRIEF DESCRIPTION OF THE DRAWINGS
[0016] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.
[0017] Figure 1 The effect of freezing on LonP1 expression in oocytes, where A is a representative image of LonP1 immunofluorescence staining in fresh and frozen oocytes, scale bar = 50 μm; B is a comparison of the relative fluorescence intensity of LonP1 staining in fresh and frozen oocytes; C is a qPCR detection of Lonp1 expression in fresh and frozen oocytes;
[0018] Figure 2The effect of freezing on oocyte protein homeostasis, where A is a representative image of unfolded protein aggregation in fresh and frozen oocytes, scale bar = 100 μm; B is a quantitative analysis of the unfolded protein level in different groups; C is a detection of stress response-related gene expression in different groups;
[0019] Figure 3 The effect of freezing on oocyte apoptosis, where A is the Annexin-V fluorescence staining image of early apoptosis of fresh and frozen oocytes, and B is the analysis of the apoptosis ratio of fresh and frozen oocytes;
[0020] Figure 4 Comparison of knockdown efficiency of LonP1 siRNAs, where A is a representative image of LonP1 immunofluorescence staining in different groups, scale bar = 50 μm; B is a quantitative analysis of LonP1 immunofluorescence intensity in different groups; C is a graph of Lonp1 mRNA expression in different groups tested by qPCR;
[0021] Figure 5 The effect of knocking down LonP1 on oocyte apoptosis, where A is a representative image of immunofluorescence staining of Caspase3 protein in different groups, scale bar = 50 μm; B is a quantitative analysis of the immunofluorescence intensity of Caspase3 protein; C is a representative image of immunofluorescence staining of BAX and BCL2 proteins in different groups, scale bar = 50 μm; D is a quantitative analysis of the BAX / BCL2 fluorescence intensity ratio;
[0022] Figure 6 Analysis of the mechanism of action of LonP1, where A is the DEGs of the si_LonP1 group and the NC group, with adjusted P < 0.05 and |log2(FC)| > 1 as thresholds; B is the cluster analysis of the DEGs of the si_LonP1 group and the NC group; C is the change trend of the selected genes in the transcriptome (si_LonP1 vs. NC); D is the qPCR detection results of the selected genes in the NC group and the si_LonP1 group; E is the GSEA enrichment analysis results;
[0023] Figure 7 It is the enrichment analysis of differentially expressed genes (DEGs) in the transcriptome, where A is the GO enrichment analysis result of DEGs, showing the top pathways in different biological processes; B is the KEGG enrichment analysis result of DEGs, showing the top pathways in different biological processes;
[0024] Figure 8Figure 3 shows the effects of inhibiting LonP1 in different ways on oocyte protein homeostasis, where A is a representative image of unfolded protein aggregation detected by TPE-MI after oocytes were treated with CDDO-me, scale bar = 100 μm; B is a quantitative analysis of the level of unfolded protein in oocytes; C is a representative image of unfolded protein aggregation in oocytes after knocking down LonP1, scale bar = 100 μm; D is a quantitative analysis of the level of unfolded protein in oocytes. DETAILED DESCRIPTION
[0025] Various exemplary embodiments of the present invention will now be described in detail. This detailed description should not be considered as limiting the present invention, but should be understood as a more detailed description of certain aspects, features, and embodiments of the present invention.
[0026] It should be understood that the terms described in the present invention are only for describing a particular embodiment and are not intended to limit the present invention. In addition, for the numerical range in the present invention, it should be understood that each intermediate value between the upper and lower limits of the scope is also specifically disclosed. The intermediate value in any stated value or stated range, and each smaller range between any other stated value or intermediate value in the described range is also included in the present invention. The upper and lower limits of these smaller ranges can be independently included or excluded in the scope.
[0027] Unless otherwise indicated, all technical and scientific terms used herein have the same meanings as those generally understood by those skilled in the art. Although the present invention describes only preferred methods and materials, any methods and materials similar or equivalent to those described herein may also be used in the implementation or testing of the present invention. All documents mentioned in this specification are incorporated by reference to disclose and describe the methods and / or materials associated with the documents. In the event of a conflict with any incorporated document, the content of this specification shall prevail.
[0028] It will be apparent to those skilled in the art that various modifications and variations may be made to the specific embodiments of the present invention description without departing from the scope or spirit of the present invention. Other embodiments derived from the present invention description will be apparent to those skilled in the art. The present invention description and examples are exemplary only.
[0029] The words “include,” “including,” “have,” “contain,” etc. used in this document are open-ended terms, meaning including but not limited to.
[0030] Example 1 Analysis of LonP1 expression in frozen oocytes
[0031] 1. Methods
[0032] 1. GV stage oocyte acquisition
[0033] Mice were intraperitoneally injected with 10 IU PMSG. After 48 hours, the mice were killed by cervical dislocation. After disinfection, the abdominal cavity was opened, the ovaries were taken out and placed in the pre-balanced HX-M199 solution, and the excess impurities were washed away by shaking back and forth. The ovaries were then transferred to a clean culture dish, and the ovaries were fully minced with a sterilized blade to release the contents, and then HX-M199 solution was added, and the cumulus oocyte complex (COC) was collected with a mouth pipette. The COC was blown and sucked with a thinner glass tube to remove the granulosa cells. The obtained GV stage oocytes were used for subsequent experiments such as freezing, in vitro maturation, and microinjection.
[0034] 2. Oocyte maturation in vitro
[0035] Preheat the M2 culture medium in advance, rinse the GV stage oocytes in HX-M199 medium with M2 medium three times, and then transfer them into a culture dish for culture (60 μL droplets are placed in about 40 oocytes). Culture them in a 37°C, 5% CO2 incubator for 12 hours. Then observe and record the discharge of the first polar body.
[0036] 3. Oocyte freezing and thawing
[0037] Open pulled straws (OPS) technology was used to vitrify GV stage oocytes. The oocytes were treated in 10% ED (preparation method: add 1 mL EG, 1 mL DMSO and 0.030 g BSA to 8 mL DPBS, stand and dissolve, and store at 4 ° C) and EDFS30 (preparation method: add 3.000 g Ficoll, 1.712 g sucrose and 0.0210 g BSA to 7.02 mL DPBS, stand and dissolve; then take 7 mL of the above solution, add 1.5 mL EG and 1.5 mL DMSO, stand and dissolve, and store at 4 ° C) solution for no more than 30 s and 25 s, and then the OPS tube containing the oocytes was directly put into liquid nitrogen for freezing and stored for at least 3 days.
[0038] When thawing, take out the OPS tube from liquid nitrogen, treat it in 0.5M SU (SU solution preparation method: add 1.919g sucrose and 0.030g BSA to 10mL DPBS, let it stand and dissolve thoroughly, and store it at 4℃) at 37℃ for 5 minutes, and finally rinse it in M2 solution containing milrinone for 3 times, transfer it to M2 culture medium containing milrinone to recover for 1 hour for subsequent experiments.
[0039] 4. Immunofluorescence staining
[0040] The oocytes were transferred into the fixative and fixed at 4°C for 1 day. The fixed oocytes were washed three times in immunofluorescence staining solution I, and then the oocytes were transferred into the permeabilization solution (preparation method: 75 μL Triton X-100 was added to 14.92 mL immunofluorescence staining solution II, and refrigerated at 4°C) for 1 to 2 hours. The permeabilized oocytes were washed three times in immunofluorescence staining solution II, and then the oocytes were transferred into the blocking solution (preparation method: 0.030 g BSA was added to 1mL of immunofluorescence staining wash solution II and stored in a refrigerator at 4°C for 1h; the corresponding primary antibody was diluted in proportion with the primary antibody diluent, and the oocytes were directly transferred into it, incubated at 4°C overnight (>12h) or incubated at 37°C for 2.5h. The negative control group used a diluent without primary antibody; washed 3 times, transferred to the corresponding secondary antibody diluted with the secondary antibody diluent, and incubated for 1h; washed 3 times, and then stained with DAPI for 5min; the oocytes were washed 3 times with DPBS and transferred to M2 droplets (1μL / drop) for photographic observation; or the oocytes were transferred to a glass slide with a mouth pipette, and photographed after the coverslip was pressed. Immunofluorescence stained oocytes were photographed and observed using a NikonA1Confocal laser confocal microscope. The fluorescence of each group of oocytes was photographed under the same immunofluorescence staining conditions and photographing parameters, and the images were exported using NIS-Elements AR software. ROIs were selected using Fiji software, and the average fluorescence intensity values per unit area within the ROI were statistically analyzed. The final mean fluorescence intensity was compared between different groups by calculating the mean of the measured values.
[0041] 5. Oocyte RNA extraction and reverse transcription
[0042] Place about 40 oocytes in a 1.5mL centrifuge tube and quickly transfer to a -80℃ refrigerator for storage. Add 500μL Trizol to each centrifuge tube, vortex and let stand on ice for 5min. Subsequently, add 100μL chloroform to each centrifuge tube, vortex and let stand on ice for 5min. Centrifuge the sample at 4℃ and 14000g for 10min, then carefully transfer the supernatant to a new 1.5mL centrifuge tube, add an equal volume of isopropanol and 1μL glycogen, vortex and let stand on ice for 5min. Centrifuge again at 4℃ and 14000g for 10min. Discard the supernatant, add 1mL of freshly prepared 75% ice ethanol to each sample, and vortex to fully dissolve the precipitate. Finally, centrifuge at 4℃ and 14000g for 5min, discard the supernatant, and fully air-dry the precipitate in the clean bench. Add 18 μL RNase-free water to each tube to fully dissolve the precipitate, then use Nanodrop spectrophotometer to detect the concentration and purity of the extracted RNA in each tube, and use RNase-free water to balance the concentration of each group of samples.
[0043] Reverse transcription was performed according to the following system: 16 μL RNA + 4 μL 5× Prime Script Buffer. Reverse transcription was performed with a reaction program of 37°C for 15 min and 85°C for 5 s; the obtained cDNA was stored in a -80°C refrigerator.
[0044] 6. Real-time fluorescence quantitative PCR (qPCR)
[0045] The qPCR test was performed using the cDNA of the sample as a template and the primers of the corresponding gene. The reaction system (10 μL) is shown in Table 1, and the primers of the corresponding gene are shown in Table 2:
[0046] Table 1 qPCR reaction system
[0047]
[0048] Table 2 Primers corresponding to genes
[0049]
[0050]
[0051] The template cDNA was mixed with the solution in the kit according to the reaction system, and added to a 96-well PCR plate in order. The qPCR reaction was performed using a Bio-Rad CFX96 Touch Real-Time PCR instrument. The reaction procedure is shown in Table 3:
[0052] Table 3 qPCR reaction procedure
[0053]
[0054] After the qPCR reaction, check whether the melting curve of each well is a single peak, and then obtain the Ct value of different genes in each group of samples. -△△Ct The algorithm is used to calculate the relative expression levels of the target genes in different groups of samples.
[0055] 8. Detection of early cell apoptosis level
[0056] Annexin-V fluorescent probe was used to detect the level of early cell apoptosis. According to the instructions of the kit, 5 μL Annexin-VFITC was added to 95 μL buffer and made into 50 μL droplets in a culture dish. Then the oocytes were placed in the droplets and incubated in a 37°C incubator in the dark for 10 min; then washed 3 times with M2 and placed in M2 droplets (1 μL / droplet). Photos were taken under the same cell staining conditions and photography parameters. In oocytes that did not undergo early apoptosis, only the zona pellucida had weak green fluorescence; while in oocytes that underwent early apoptosis, green fluorescence was present in both the zona pellucida and the cell membrane of the oocyte.
[0057] 9. Detection of unfolded protein content in cells
[0058] TPE-MI fluorescent probe was used to detect the level of unfolded proteins in cells. TPE-MI was diluted to 50 μmol / L using M2 culture medium, and 50 μL microdroplets were made in a culture dish and placed in a 37°C incubator for preheating for 20 min; then the oocytes were placed in the microdroplets and incubated in a 37°C incubator in the dark for 30 min; then washed 3 times with M2 and placed in M2 microdroplets (1 μL / droplet). Under the same cell staining conditions and photography parameters, Fiji software was used to select a specific region of interest (ROI), and the average fluorescence intensity value per unit area in the ROI was statistically analyzed. The final average fluorescence intensity between different groups was compared by calculating the average of the measured values.
[0059] 10. Data Analysis
[0060] The experimental data were analyzed by independent sample t test and one-way ANOVA using GraphPad Prism 9 software. All experiments were repeated at least 3 times, and the data were expressed as mean ± standard error of the mean (mean ± SEMs). When P < 0.05, it was considered statistically significant.
[0061] 2. Results
[0062] 1. Cryopreservation leads to a decrease in LonP1 expression in oocytes
[0063] Immunofluorescence staining and qPCR were used to examine the changes in LonP1 and its mRNA levels. Immunofluorescence staining showed that the expression of LonP1 protein in GV-stage oocytes was significantly reduced after freezing (0.86±0.04 vs. 1.00±0.03, P<0.05, Figure 1A, B), qPCR results also showed that the expression of Lonp1 mRNA in GV stage oocytes was significantly decreased after cryopreservation (0.82±0.04 vs. 1.00±0.01, P<0.05, Figure 1 C). The above results indicate that cryopreservation will lead to a decrease in the expression of LonP1 in GV stage oocytes.
[0064] 2. Effects of cryopreservation on oocyte protein homeostasis
[0065] LonP1 is involved in maintaining cellular protein homeostasis. In order to further determine the reasons for the decrease in the in vitro maturation rate of oocytes after vitrification and the potential role of LonP1 in freezing injury, this experiment detected the accumulation level of unfolded proteins in oocytes. The level of unfolded proteins in cells was detected by TPE-MI dye. In frozen oocytes, the accumulation level of unfolded proteins was significantly increased compared with that in fresh oocytes (11.49±0.28vs.9.35±0.21, P<0.01, Figure 2 A, B). At the same time, the expression changes of stress-related genes before and after freezing were detected. After cryopreservation, the expression of stress response genes in oocytes showed an upward trend, among which mtHsp70 and Chop genes were significantly upregulated ( Figure 2 C). These results suggest that freezing can lead to disruption of protein homeostasis and cellular stress.
[0066] 3. Effect of cryopreservation on early apoptosis of oocytes
[0067] Compared with the fresh group (7.94±3.57%), the proportion of early apoptosis in frozen oocytes (89.58±6.25%, P<0.01) was significantly increased ( Figure 3 A, B; the solid line marks the oocyte cell membrane, and the dotted line marks the oocyte zona pellucida).
[0068] Example 2 Effect of LonP1 siRNA injection on oocyte apoptosis
[0069] 1. Methods
[0070] The methods of oocyte acquisition, in vitro maturation, immunofluorescence staining, and qPCR were the same as those in Example 1. The difference from Example 1 was that fresh GV-stage oocytes were microinjected with siRNA that inhibited LonP1 expression to construct oocytes with low LonP1 expression, and the effects of knocking down LonP1 on oocyte apoptosis and protein homeostasis were evaluated. The specific scheme is as follows:
[0071] 1. Oocyte microinjection
[0072] Nikon microinjection system and Eppendorf microinjection pump were used to microinject oocytes. The interference sequence of LonP1 was injected into GV stage oocytes to inhibit its expression, and the control group was injected with a meaningless interference sequence (NC). After microinjection, oocytes were placed in M2 culture medium containing milrinone to inhibit maturation and culture for 24h. Surviving GV stage oocytes were subsequently collected for subsequent experiments. The microinjection sequence is shown in Table 4.
[0073] Table 4 Microinjection siRNA sequences
[0074]
[0075] 2. Transcriptomics sequencing
[0076] After in vitro maturation of the microinjected oocytes, the MII stage oocytes injected with nonsense sequence (NC) and knockdown sequence (si_LonP1) were collected respectively. The number of oocytes in each repeated sample of each group was 30, and each group was repeated 3 times in parallel. The oocytes were transferred into the cell lysis buffer dedicated to RNA-seq to ensure that the final volume was 4μL, and then Nuclease-free water was added to make up 5μL, and temporarily stored in a -80℃ refrigerator.
[0077] The RNA purity was detected using a Nanodrop spectrophotometer, and the magnetic beads with Oligo (dT) were enriched to selectively enrich the mRNA, and the enriched mRNA was broken down into short fragments by fragmentation buffer. Single-stranded cDNA was synthesized by reverse transcription using random hexamers and mRNA as templates, and then double-stranded cDNA was synthesized by adding buffer, dNTPs and DNA polymerase I. Double-stranded cDNA was purified by using AMPure XP magnetic beads to remove impurities. The purified double-stranded cDNA was treated with end repair, A addition and splicing addition. The double-stranded cDNA was size-selected using AMPure XP magnetic beads and PCR amplified to construct a cDNA library.
[0078] The insert size of the library is detected using Agilent 2100, and the effective concentration of the library is accurately quantified by qPCR; the library is then pooled. The principle of sequencing by synthesis is used to detect the fluorescence released by a newly added fluorescently labeled dNTP. The sequencer captures the fluorescence signal and converts it into a sequencing peak, thereby obtaining the sequence information of the fragment to be tested.
[0079] The raw reads were quality controlled to obtain clean reads; the clean reads were compared with the reference sequences; the gene structure of the sequence was analyzed, including new transcript prediction, variable splicing analysis, and SNP / INDEL analysis; gene expression was quantitatively analyzed, and then the differences were compared. Genes with adjusted P < 0.05 and |log2 (foldchange, FC) | ≥ 1 were considered differentially expressed genes (DEGs); GO enrichment analysis and KEGG enrichment analysis were performed on DEGs to deeply analyze and predict potential functions.
[0080] Gene Set Enrichment Analysis (GSEA) was performed on the sequenced genes using the Gidio data analysis cloud platform (https: / / www.omicshare.com / ) to explore the change trend at the pathway level. Protein-protein interaction networks (PPI) in potential pathways were predicted, analyzed, and visualized using STRING (https: / / string-db.org / ) and Cytohubba and CytoNCA plug-ins of Cytoscape software.
[0081] 2. Results
[0082] 1. siRNA sequence selection
[0083] The knockdown efficiency of four LonP1 siRNAs was detected by protein ( Figure 4 A, B) and mRNA ( Figure 4 C) The success of LonP1 knockdown was demonstrated at two levels. In subsequent experiments, 819 sequences were selected for knockdown and grouped as "si_LonP1", and the group injected with meaningless sequences was grouped as "NC".
[0084] 2. Effect of knockdown of LonP1 on oocyte apoptosis
[0085] The expression of apoptotic protein Caspase3 was detected by immunofluorescence staining. The image results showed that after knocking down LonP1, the expression of Caspase3 protein in oocytes increased significantly (12.54±0.80 vs. 9.46±0.59, P<0.01, Figure 5 A, B). The expression changes of apoptosis-related proteins BAX and BCL2 were also examined. Fluorescence images showed that the BAX / BCL2 ratio increased significantly in the knockdown group (0.63±0.07 vs. 0.46±0.05, P<0.05, Figure 5 The above results indicate that knockdown of LonP1 increased the level of oocyte apoptosis.
[0086] 3. Transcriptomics results show that LonP1 regulates protein homeostasis and oocyte apoptosis
[0087] The samples were analyzed for intergroup differences, and DEGs were screened with the thresholds of adjusted P < 0.05 and |log2(FC)| > 1. A total of 182 DEGs were detected, of which 111 were upregulated and 71 were downregulated ( Figure 6 A). Cluster analysis of DEGs Figure 5 As shown in B. Several genes were randomly selected for qPCR testing. The results showed that the change trends of these genes were consistent with the sequencing results, proving that the sequencing results were highly reliable ( Figure 6 C, D). GSEA enrichment results showed that the apoptosis pathway was significantly upregulated in the si-LonP1 group ( Figure 6 E).
[0088] GO functional enrichment analysis was performed on DEGs. DEGs were concentrated in three aspects: biological process, molecular function, and cellular component. In terms of biological process, DEGs were mainly concentrated in primary metabolic process, nitrogen-containing compound metabolic process, and cellular component biogenesis; in terms of molecular function, DEGs were mainly concentrated in organelle membrane, cell trailing membrane, etc.; in terms of cellular component, they were mainly concentrated in molecular adapter activity, cell adhesion molecule binding, protein-macromolecule adapter activity ( Figure 7 A). KEGG functional enrichment analysis of DEGs showed that DEGs were mainly enriched in biological processes such as ubiquitin-mediated proteolysis, tight junction, Epstein-Barr virus infection, and endocytosis ( Figure 7 B).
[0089] Example 3 Effect of low expression of LonP1 on oocyte protein homeostasis
[0090] 1. Methods
[0091] The methods for oocyte acquisition, in vitro maturation, and immunofluorescence staining are the same as those in Example 1. The difference from Example 1 is that after fresh GV stage oocytes are acquired, LonP1 inhibitor CDDO-Me is used to inhibit LonP1 expression, and the effect of low LonP1 expression on oocyte in vitro maturation is further analyzed. The specific scheme is as follows:
[0092] 1. CDDO-Me solution preparation
[0093] 989 μL DMSO was added to 500 mg CDDO-me (M=505.7 g / mol) to prepare a 1 mmol / L concentrated stock solution, which was frozen and stored at -20° C. This concentrated stock solution was diluted with cell culture medium when used.
[0094] 2. Experimental Grouping
[0095] 1, 2, and 4 μmol / L CDDO-me were added to the IVM solution, respectively. After 12 h of in vitro maturation, the extrusion of oocyte polar bodies was evaluated.
[0096] 2. Results
[0097] 1. CDDO-Me concentration screening
[0098] The results showed that the oocyte polar body extrusion rate in the 4 μmol / L CDDO-Me treatment group decreased significantly (Table 5), indicating that inhibiting the activity of LonP1 would affect the normal maturation of oocytes. 4 μmol / L CDDO-me was selected for subsequent experiments of the present invention.
[0099] Table 5 Effects of CDDO-me treatment on oocyte maturation in vitro
[0100]
[0101] Note: The experimental results are expressed as mean ± standard error. Different superscript lowercase letters indicate significant differences in the same column (P < 0.05).
[0102] 2. Effect of low expression of LonP1 on oocyte protein homeostasis
[0103] LonP1 inhibitor CDDO-Me or LonP1 siRNA microinjection was used to obtain oocytes with low LonP1 expression, and the effect of low LonP1 expression on oocyte protein homeostasis was analyzed. The results showed that after adding the inhibitor, the level of unfolded proteins in oocytes increased significantly (29.78±0.53 vs. 21.45±0.45, P<0.01, Figure 8 A, B); Similar to oocytes after vitrification, the level of unfolded proteins in oocytes also increased significantly after knocking down LonP1 (25.82±0.71 vs. 17.73±0.80, P<0.01, Figure 8 C, D). Therefore, the reduction of LonP1 activity leads to the accumulation of unfolded proteins in cells and the disruption of protein homeostasis.
[0104] In summary, Example 1 shows that the decrease in LonP1 expression is closely related to the imbalance of protein homeostasis and increased apoptosis level in frozen oocytes. Example 2 shows that microinjection of LonP1 siRNA can lead to a decrease in LonP1 levels and an increase in apoptosis levels in oocytes. Transcriptomics confirms that LonP1 can participate in the regulation of protein homeostasis and apoptosis. Example 3 further shows that microinjection of LonP1 siRNA or treatment with the LonP1 inhibitor CDDO-Me can lead to an imbalance in oocyte protein homeostasis. The above results show that oocytes with low LonP1 expression can simulate oocyte cryoinjury, especially in terms of protein homeostasis imbalance, increased apoptosis levels and other indicators. Therefore, microinjection of LonP1 siRNA or treatment of oocytes with CDDO-Me can be used as a biological model for studying oocyte cryoinjury and stress response.
[0105] The embodiments described above are only descriptions of the preferred modes of the present invention, and are not intended to limit the scope of the present invention. Without departing from the design spirit of the present invention, various modifications and improvements made to the technical solutions of the present invention by ordinary technicians in this field should all fall within the protection scope determined by the claims of the present invention.
Claims
1. Application of reagents that reduce the expression of LonP1 gene in oocytes in constructing an oocyte cryoinjury model.
2. The use according to claim 1, characterized in that: The oocyte is a GV stage oocyte.
3. A method for constructing an oocyte cryoinjury model, characterized in that: The method comprises the step of treating the oocyte with an agent for reducing the expression level of the LonP1 gene.
4. The method according to claim 3, characterized in that The reagents for reducing the expression level of the LonP1 gene include a LonP1 inhibitor and a siRNA for silencing the LonP1 gene.
5. The method according to claim 4, characterized in that The siRNA includes a sense strand as shown in SEQ ID NO.3 and an antisense strand as shown in SEQ ID NO.
4.
6. The method according to claim 4, characterized in that The LonP1 inhibitor includes CDDO-me.
7. The method according to claim 1, characterized in that The oocyte is a GV stage oocyte.
8. The oocyte cryoinjury model constructed by the method according to any one of claims 3 to 7.
